MaxCyte, Inc. (MXCT) Guidance & Earnings Results

On 2026-10-14 MaxCyte, Inc. raised guidance: "FY2026 revenue raised to ~$34M from $30-32M; core business revenue raised to ~$28M from $25-27M; SPL revenue raised to ~$6M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MXCTMaxCyte, Inc.Follow MXCT — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 144.5M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
14 Oct 26	Raised	FY2026 revenue raised to ~$34M from $30-32M; core business revenue raised to ~$28M from $25-27M; SPL revenue raised to ~$6M from ~$5M · full year
12 Aug 26	Reaffirmed	FY2026 revenue $30M-$32M; core $25M-$27M; SPL ~$5M; cash at least $130.5M · full year
12 May 26	Reaffirmed	FY2026 total revenue $30-32M; Core revenue $25-27M; SPL Program-related ~$5M ($3M milestones, $2M royalties); year-end cash at least $136M · full year
24 Mar 26	Lowered	FY2026 total revenue $30-32M (vs FY2025 $33.0M); core revenue $25-27M; SPL program-related $5M; expects to end 2026 with at least $136M cash · full year
12 Nov 25	Reaffirmed	Core revenue flat to -10% YoY; SPL program-related ~$5M; cash $152-155M · full year
5 Nov 25	Reaffirmed	FY2025 core revenue flat to -10% decline vs 2024; SPL program-related revenue ~$5M; year-end cash $152-155M · full year
6 Aug 25	Lowered	FY2025 core revenue flat to -10% YoY (from prior growth); SPL program-related revenue ~$5M · full year

MaxCyte, Inc. — questions

What guidance did MaxCyte, Inc. give?: On 2026-10-14: "FY2026 revenue raised to ~$34M from $30-32M; core business revenue raised to ~$28M from $25-27M; SPL revenue raised to ~$6M from ~$5M"
When does MaxCyte, Inc. report earnings?: MaxCyte, Inc.'s next earnings report is expected on 2026-11-10.

Every figure on this page comes from MaxCyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.